Literature DB >> 7784805

Low prevalence of anti-HCV antibodies among Italian Air Force recruits.

R D'Amelio1, T Stroffolini, P M Matricardi, R Nisini, M E Tosti, M Trematerra, U Villano, M Rapicetta, A Mele.   

Abstract

In 1990, the prevalence of antibodies to hepatitis C virus (anti-HCV) was assessed among 4,978 Air Force recruits aged 18-26 years coming from all regions of Italy. Positivity to anti-HCV was found by both IIIrd generation EIA and RIBA in 24 (0.48%) study participants. The prevalence was twice as high in Southern Italy and the islands as in Northern and Central Italy (0.76% vs. 0.35%), a difference which was not statistically significant. The results of multiple logistic regression showed that no sociodemographic variable (region of birth, father's years of education, number of siblings) was associated with anti-HCV positivity. No anti-HCV-positive individual was positive for HBsAg. Anti-HCV positivity was found in 0.8% (2/236) of the participants who were positive for anti-HBc and in 0.5% (22/4742) of those who were anti-HBc negative, also a difference which was not statistically significant. Thus no association was found between HCV and HBV infections. These findings indicate that in Italy, HCV infection is an uncommon event among young adult males.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784805

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  Hepatitis C virus infection in households of anti-HCV chronic carriers in Italy: a multicentre case-control study.

Authors:  E Sagnelli; G B Gaeta; F M Felaco; T Stroffolini; S Conti; A Glielmo; F Piccinino; G Giusti
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

2.  Cross-sectional assessment of prevalence and correlates of blood-borne and sexually-transmitted infections among Afghan National Army recruits.

Authors:  Catherine S Todd; Abdul Nasir; G Farooq Mansoor; Sayed M Sahibzada; Linda L Jagodzinski; Farzana Salimi; M Naim Khateri; Braden R Hale; R Vincent Barthel; Paul T Scott
Journal:  BMC Infect Dis       Date:  2012-08-21       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.